NCT00825162

Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years

A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged >= 6 Months to < 18 Years

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,992 (actual)
• Sponsor: Seqirus · Industry
• Sex: All
• Age: 6 Months – 17 Years
• Healthy volunteers: Accepted

Summary

A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged \>= 6 Months to \< 18 Years

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	CSL Limited Influenza Virus Vaccine	Single or two-vaccination regimen (0.25mL)
BIOLOGICAL	CSL Limited Influenza Virus Vaccine	Single or two-vaccination regimen (0.5mL)
BIOLOGICAL	CSL Limited Influenza Virus Vaccine	Single vaccination regimen (0.5mL)

Timeline

• Start date: 2009-03-01
• Primary completion: 2010-02-01
• Completion: 2010-02-01
• First posted: 2009-01-19
• Last updated: 2018-05-23
• Results posted: 2011-07-29

Locations

7 sites across 1 country: Australia